DR alpha chain ; HLA class II histocompatibility antigen ; HLA class II histocompatibility antigen DR alpha chain ; HLA DRA ; HLA DRA1 ; HLA-DRA ; HLADRA1 ; Major histocompatibility complex class II DR alpha ; MHC cell surface glycoprotein ; MHC class II antigen DRA
Categories
Primary Antibodies
Cellular Localization
Cell Surface
Chromosome Location
6p21.3
Clonality
Monoclonal
Description
MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkinā€™s disease cases a significant percentage of affected lymph node cells were detected. ĀĀĀ
Host
Mouse
Immunogen
Spleen cells of a patient with hairy cell leukemia (Daudi cells)
Isotype
IgG3 Kappa
Positive Control
Ramos, Daudi or HuT78 cells. Tonsil or lymph node
Reactivity
Human, Monkey
Recombinant
FALSE
Regulatory
RUO
Swissprot
P01903
Uniprot
520048
Gene Id
3122
Buffer
200μg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
Concentration
1.0mg/ml
Description
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Purity
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Applications
FACS, IF
Description
Optimal dilution for a specific application should be determined., FACS ; IF
Dilution
FACS
0.5-1μg/million cells in 0.1ml
IF
0.5-1μg/ml
Reviews of Anti-HLA-DRA (MHC II) Antibody BHA10201848